CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Class Ic antiarrhythmic
Updated · Methodology
Mechanism
Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Flecainide, a class IC antiarrhythmic, slows conduction in the heart. According to the Spanish SmPC, flecainide prolongs the QT interval and widens the QRS complex by 12–20%. According to the US label, QT lengthens with dose by about 8% on average, mostly because the QRS widens. Rare cases of torsade de pointes have been reported (flecainide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The Spanish domperidone SmPC explains that combinations with QT-prolonging drugs are contraindicated because pharmacodynamic or pharmacokinetic interactions raise the risk of QT prolongation (AEMPS). CYP2D6 takes part in flecainide metabolism, and CYP3A4 is the main enzyme for domperidone. The documents do not name either drug as an inhibitor of the enzymes that metabolise the other. They also give no data on how one drug changes the level of the other (flecainide and domperidone SmPCs, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Like other antiarrhythmics, flecainide can cause new or worse arrhythmias, including more frequent extrasystoles and more severe ventricular tachycardia, as well as atrioventricular block, a slow heart rate and sinus arrest (flecainide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and label, US Food and Drug Administration, FDA). With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS). Low or high potassium also alters the effect of flecainide (flecainide FDA label).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs, and its list for this group is not exhaustive (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Flecainide is not among the examples. However, its own Spanish SmPC states directly that it prolongs the QT interval, and its US label states that QT lengthens with dose. The contraindication therefore covers flecainide too (flecainide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure, and flecainide in heart failure (domperidone and flecainide SmPCs, AEMPS). Before starting flecainide, correct low or high potassium and other electrolyte disturbances, as well as severe bradycardia or marked hypotension (flecainide SmPC, AEMPS). If the PR interval reaches 0.30 seconds or QRS reaches 0.18 seconds, continue flecainide with caution and consider a lower dose. Stop flecainide in second- or third-degree atrioventricular block unless a pacemaker is in place (flecainide FDA label). If domperidone and flecainide have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Flecainide acetate tablet (Amneal Pharmaceuticals of New York LLC) – Prescribing Information – CAST trial, CYP and CCB interactions (2017)– FDA Tambocor label, Boxed Warning (CAST); Drug Interactions §7; DailyMed setid ee9595d5-08a1-4529-9215-ddc3c7f929c4
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Flecainida, Apocard 100 mg (nº registro 57532), sección 4.5 (2025)– AEMPS, CIMA, nº registro 57532 (Apocard 100 mg comprimidos, Viatris Healthcare), revisión 06/2025, secciones 4.3, 4.4 y 4.5